+ All Categories
Home > Documents > Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry-Sayeh...

Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry-Sayeh...

Date post: 20-Feb-2017
Category:
Upload: sayeh-majzoob
View: 373 times
Download: 0 times
Share this document with a friend
110
Sayeh Majzoob Pharm. D., Ph. D. in Pharmaceutics; Pharma MBA Email address: [email protected] Cellphone: +98 912 1366744 Based on: ISPE Good Practice Guide-Technology Transfer-2003/2014 WHO Technical Report Series, No. 961, 2011, Annex 7, WHO guidelines on transfer of technology in pharmaceutical manufacturing Guideline for Technology Transfer-NIHS-Japan-2012 ICH Q10-Scale-up & Technology Transfer as a Part of Pharmaceutical Quality Systems 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 1
Transcript
  • Sayeh MajzoobPharm. D., Ph. D. in Pharmaceutics; Pharma MBA

    Email address: [email protected]: +98 912 1366744

    Based on: ISPE Good Practice Guide-Technology Transfer-2003/2014 WHO Technical Report Series, No. 961, 2011, Annex 7, WHO guidelines on

    transfer of technology in pharmaceutical manufacturing Guideline for Technology Transfer-NIHS-Japan-2012 ICH Q10-Scale-up & Technology Transfer as a Part of Pharmaceutical Quality

    Systems

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 1

  • Understand scope and stages in technology transfer, and its successcriteria including:

    Forming the transfer team and developing the project charter Consolidating knowledge for transfer and developing a technology

    transfer proposal Identifying risks, conducting risk assessments and developing technology

    transfer plan Executing the transfer Finalizing the transfer and performing the review Pitfalls

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 2

  • The ever-changing business strategies of pharmaceutical companies increasinglyinvolve intra- and inter-company transfers of technology for reasons such as theneed for:

    Product life cycle (from R&D to pilot/clinical scale and Industrial scale) Increasing access to medicine with better prices (NGO initiatives/ Social Responsibility

    ) Additional capacity and freeing up capacity for new products Relocation of operations or consolidations and mergers Access to new markets on condition of Technology Transfer In-licensing Out-licensing Contract manufacturing

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 3

    Research &development,

    ClinicalPhases Scale-up

    Post-approval

    phaseProductionand launch

    Scope of ISPE Technology transfer Guide

  • ISPE 2003/2014 and WHO Technical Report Series,No. 961, 2011)

    The systematic [Step-by-step andplanned] procedure that is followed inorder to pass the documented knowledgeand experience gained during developmentand/or commercialization to an appropriate,responsible, and authorized party.

    Technology transfer embodies both thetransfer of documentation AND thedemonstrated ability of a Receiving Unit toeffectively perform the critical elements oftransferred technology, to the satisfaction ofall parties and any, or all, applicableregulatory bodies.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 4

  • ICH Q10- 3.1.2 The goal of technology transfer activities is to transfer product and

    process knowledge between development and manufacturing, andwithin or between manufacturing sites to achieve productrealization. This knowledge forms the basis for the manufacturingprocess, control strategy, process validation approach and ongoingcontinual improvement.

    Technology transfer (TT) comprises a science and risk-based principlesincluding: ICH Q8 Pharmaceutical Development ICH Q9 Quality Risk Management ICH Q10 Pharmaceutical Quality System ICH Q11 Development and Manufacture of Drug Substances (Chemical

    Entities and Biotechnological/Biological Entities)

    Transfer of technology requires a: Documented, planned approach using trained and knowledgeable

    personnel working within a quality system, with documentation of datacovering all aspects of development, production and quality control.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 5

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 6

    Transfer of expertise and technology associated with: Analytical Methods APIs Dosage Forms

    Useful from the earliest phases in a products life cycle through to, andincluding, post approval transfers

    ISPE and WHO guides currently does not explicitly offer specific guidance related to biologicalproducts, blood related products, medical gasses, and medical devices.The concepts described therein are, however, broadly applicable and may be useful in theseareas as well.

  • Development and optimization are dynamic as they relate to the life cycle ofa product, process, or method, and as a result:

    Development activities are expected to be adequately complete,for the specific stage in the life cycle, and appropriatelydocumented prior to initiation of transfer.

    However, the baseline level of specifications or performance criteria mightprogressively improve (changes, variations, new methods, .).

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 7

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 8

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 9

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 10

  • If a Receiving Unit can routinely [consistently] reproduce the transferred product, process, ormethod against a predefined set of specifications as agreed with a Sending Unit and /or aDevelopment Unit, the transfer is considered successful.

    Depending on the reason for the technology transfer, the criteria for success may vary,however, in all cases, because this work is in a regulated environment,documentation for the transfer effort is critical.

    It is critical that a clear objective for any technology transfer project be developed.

    It is also critical that a project team comprised of individuals from both the Sending Unit andthe Receiving Unit is established and that there is a precise understanding of each teammembers role and responsibility prior to initiation of the technology transfer project.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 11

  • Skill alone will not ensure a successful technology transfer project.

    Once a project has been identified and a team chosen, a clear and realistic projectimplementation, temporal plan is required to guide the project, manage expectations,and handle the inevitable deviations and changes that may present themselves duringimplementation.

    Along with that plan comes the need to consider the temporal relationship betweenthe various tasks associated with a successful technology transfer.

    It should be clearly understood that each technology transfer assignment is unique andit is, therefore, impossible to provide a generic technology transfer plan.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 12

  • Effective Kick-off sessions so the team membersget to know each-other

    Be friendly, positive, helpful, polite, fair, unbiased,flexible, professional and mature, understandingand empathetic

    Teleconferences (TCs) Cellphone/Desktop apps such as Skype, IMO,

    Telegram, Text messages, Whatsapp, . canexpedite many issues (though unofficial, viewthem as phone calls; Document and communicatethem officially immediately afterwards)

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 13

    Group Emails for information only Keep the relevant people in the loop, and

    the assistants/ substitutes in cc to follow-up in case the focal person is unavailable

    If you want an email unanswered and tobe overlooked, address it directly tomore than 1 person!

    Just pick up the phone Leave your desk and meet in person SharePoint Agendas Minutes of meetings Gantt charts (Excel, Word, MSP),

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 14

  • Pre-transfer Build transfer team and develop project charter (CEO/DIRECTORS level- estimates) Consolidate detailed knowledge for transfer and develop technology transfer protocol

    (MANGERS level document-more in details and more accurate) Procurements/Supplies Regulatory Trainings Technical/Trouble shooting batches/runs Process/Procedure qualification/validation (depending on the stage of transfer, Pivot

    batches, Bio-batches,.. can be included) Perform review Need to repeat any step Finalize transfer and Wrap-up Lessons-learned knowledge database

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 15

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 16

    Based on: ISPE Good Practice Guide-Technology Transfer-2003/2014 WHO Technical Report Series, No. 961, 2011, Annex 7, WHO guidelines on

    transfer of technology in pharmaceutical manufacturing Guideline for Technology Transfer-NIHS-Japan-2012 ICH Q10-Scale-up & Technology Transfer as a Part of Pharmaceutical

    Quality Systems

  • Pre-transfer Build transfer team and develop project charter (CEO/DIRECTORS level- estimates) Consolidate detailed knowledge for transfer and develop technology transfer protocol

    (MANGERS level document-more in details and more accurate) Procurements/Supplies Regulatory Trainings Technical/Trouble shooting batches/runs Process/Procedure qualification/validation (depending on the stage of transfer, Pivot batches,

    Bio-batches,.. can be included) Perform review Need to repeat any step Finalize transfer and Wrap-up Lessons-learned knowledge database

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 17

  • Memorandum of Understanding (MoU) Very general 2 Bi-partite MoUs or 1 Tri-partite (inter- or Intra- sites) Name of products Scope Validity date Governing law (sometimes non-binding) .

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 18

  • General questionnaire (if applicable) Name/ Contact info/ Key persons and experience/

    Company history/ Organization Chart Governmental/ Privately-owned/ Member of a

    holding/ Possible contracts (Conflict of interests) Number of staff in each department: Manufacturing/ Packaging/

    Warehouses/ QA/ QC/ Engineering/ IT,. (Ratios suitable based on thecompany operations/size)- Turnovers

    Shifts/ Working Hours Dosage forms Cytotoxics/ Penicliins/ Cephalosporines/ Penems/

    Sex hormones/ Biologics/ Herbal/ Live vaccines/hazardous.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 19

    In which activities are they willing to assist:Procurement, QC, Technical QC equipment: Types and Brands/ Models/ Numbers Stability Chambers, RoomsManufacturing/ Packaging technology: Types and

    Brands/ Models/ Minimum and Maximum workingcapacities/ Numbers Facilities surface areas: Warehouses/ Manufacturing/

    Packaging/ QC (Physicochemical, Microbiological) Engineering utilities: BMSs, EMSs, . QMS Certificates (GMP, ISO, Audits by international

    companies,) Current and Pipe-line product list

  • Due Diligence Visits/ Audits Initially a visit by the focal person for smooth Audit planning An opening session, Site walking tour, Documentation review, Wrap-up Visit/ Audit reports and possible required CAPAS with timeline

    Supply and Procurement/ Financial agreement 2 Bi-partite agreements or Tri-partite Transparent details of financial aspects and responsibilities in procurements, QC

    tests/ Technical and Validation batches expenses/ Routine batch expenses

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 20

  • Technical and Qualityagreement

    2 Bi-partite agreements or Tri-partite

    Confidentiality agreement(CDA-NDA)

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 21

  • Pre-transfer

    Build transfer team and develop project charter (CEO/DIRECTORS level- estimates)

    Consolidate detailed knowledge for transfer and develop technology transfer protocol (MANGERS leveldocument-more in details and more accurate)

    Procurements/Supplies Regulatory Trainings Technical/Trouble shooting batches/runs Process/Procedure qualification/validation (depending on the stage of transfer, Pivot batches, Bio-batches,..

    can be included) Perform review Need to repeat any step Finalize transfer and Wrap-up Lessons-learned knowledge database

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 22

  • Setting focal persons in each party and having an introduction session (preferably face-to-face) Promoting project management skills, being organized, knowing the basics of modern

    communication Clarifying responsibilities and authorities: no overlaps, gaps (RACI CHART, WBS) Emphasizing team-work spirit, keeping respective staff in the loop, not monopolizing, being fair,

    fostering communication skills, no blame-shifting Encouraging open channels of communication: responding on time and willingly Considering language skills Choosing members based on technical knowledge of the process/ product: An experienced team Setting Channels of communication (Emails, TCs; Having required forms, templates, SOPs, WIs,

    Flowcharts, Protocols) Team members not working as isolated islands, since timings and tasks are often very much

    interrelated and intertwined

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 23

    Microsoft WordDocument

  • Example of project charter (a high-level CEO/DIRECTORS document -estimates-using previous history): DIRECTORS SHOULD BE INFORMED OF THE GENERALITIES OFTHE PROJECT BEFOREHAND, AND THEY SHOULD SUPPORT IT!

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 24

    Project name Approved by (Support by higher directors) Revision history Executive summary Goals Scope General Time-line and main milestones General risks (QRM):

    to brief higher directors on the criticality andreasons behind decisions

    Resources estimate (the Ms): Man Material Machinery Methods/Documents Money Management

    General WBS (Responsibilities matrix)

    Microsoft WordDocument

  • Pre-transfer Build transfer team and develop project charter (CEO/DIRECTORS level- estimates)

    Consolidate detailed knowledge for transfer and develop technologytransfer protocol (MANAGERS level document-more in details and moreaccurate)

    Procurements/Supplies Regulatory Trainings Technical/Trouble shooting batches/runs Process/Procedure qualification/validation (depending on the stage of transfer, Pivot batches, Bio-batches,.. can

    be included) Perform review Need to repeat any step Finalize transfer and Wrap-up Lessons-learned knowledge database

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 25

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 26

    APPROVALS (by all relevant key people) SUMMARY RESPONSIBILITIES (name the persons) REGULATORY TRAININGS NEEDED PRODUCTS AND ACTIVITIES TO BE TRANSFERRED HYGIENE SAFETY ENVIRONMENT PRODUCT/ PROCESS HISTORY REVIEW BEFORE

    TRANSFER ANALYTICAL TRANSFER MANUFACTURING PROCESS TRANSFER (if applicable)

    RAW MATERIAL AND SUPPLIERS PACKAGING MATERIAL (if applicable) STABILITY (If applicable) GAP ANALYSIS QRM (might be more detailed than the initial

    QRM in the project charter) DOCUMENTS REQUIRED (SOPs, Protocols,

    Checklists, Forms, Flowcharts, ) PLANNING (timelines) RELEASE/ APPROVAL CONDITIONS LOGISTICS

    Microsoft WordDocument

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 27

  • Gap analysis is Identification of all critical elements of a process/facility/staff which are available at the Sending Unit but are missing fromthe Receiving Unit, and to find and implement solutions for them.Receiving Unit readiness assessmentDemonstration runs; Technical batches; Media fillsProcessing/ Method GapsInformation-training-experience gapsFacility gaps

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 28

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 29

  • To achieve a higher assurance on qualityTo reduce the probability of failureTo systematically break down complex

    processes and their possible failuresTo save time and resourcesTo facilitate and prioritize decision makingTo communicate critical points to all team

    membersTo think critically about even simple

    processes and gain in-depth knowledge ofeach, and their consequences

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 30

    QRM (might be more detailed than theinitial QRM in the project charter);ICH Q9 Define stages and process flowchart Identify failure modes and their effects Root cause analysis: 5 whys, 2-Hs, Fish

    bone diagram (Ishikawa), A3 problem-solving, PDCA, or other methods

    Clear ranking basis FMEA, PHA, HACCP Listing current control measures Prioritizing failure modes Implementing CAPAs based on priorities;

    Risk mitigation Final review and assessment

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 31

  • A history of the process including:The development and process rationale,justification of specification ranges, andprior validation activities, hold times, CPP,CQAs, Control strategies

    Technology transfer protocol, whichcaptures the critical manufacturing processparameters

    Technology transfer report templatedetailing the success (or failure) criteria andreport of the technology transfer

    Batch record and Process Flow chartsand the relevant SOPs, Protocols, WIs,tips

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 32

    Specifications and supplier list of material,machinery, equipment, reagents, size-parts...

    Relevant Health, Safety and Environmentdocuments: MSDS of material,Containment and leakage measures

    Transport validation protocol and reporttemplate (in case of transport of API,Bulks, Intermediates.)

    Sometimes the Focal Unit or the Receiving Unit participate in preparation of these documents.

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 33

  • Sampling plans, Sampling techniques,

    Frequencies, IPC and IPQC samplings

    Methods of analysis and tips

    Analytical transfer protocol

    Stability study protocol and report

    template

    Cleaning instructions

    Rework procedure

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 34

    Required training documents

    Artworks

    Annual product review documentation

    and template (include process capability,

    process control trend summaries, and

    process variations and the investigation

    of those variations, follow-up actions,

    and a rationale and summary of

    reworked product)

  • General Technology Transfer Process description andFlowchart

    Project Charter

    Contracts

    Project general and detailed time-line (Gantt charts, Pand inter-dependencies (Network Diagram)

    Responsibility Matrix and Work Breakdown Structure(RACI CHART, WBS)

    Audits and Visits and CAPA follow-up forms

    Documents Transfer Receipt forms

    Material Transfer Receipt forms

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 35

    Training needs and records

    QRM documents in technology transferprocess

    Material/ Equipment procurement forms

    Artworks and packaging material preparationSOPs

    Regulatory processes SOPs

    Minutes of meetings

    Records of Technical batches

    Lessons-learnt database

    Sometimes the Sending Unit or the Receiving Unit participate in preparation of these documents:

    Microsoft WordDocument

  • Site VMP (at least parts which are relevant to the

    Technology transfer project at hand)

    Qualification documents of all relevant utilities,

    machinery, equipment

    QRM, PHA at the receiving site

    Technology Transfer Validation Protocol and report

    (both trouble-shooting trial technical runs and the

    main runs)

    Stability study report

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 36

    Customized bi-lingual Batch Manufacturing and

    Control Records and SOPs, WIs, Forms, (both for

    trouble-shooting trial technical runs and the main

    runs)

    Deviations and Change control documents

    PQR

    Cleaning validation documents, taking into account

    the transferred products

    Sample retention

    Local Dossier (if relevant)

  • Pre-transfer Build transfer team and develop project charter (CEO/DIRECTORS level- estimates) Consolidate detailed knowledge for transfer and develop technology transfer protocol

    (MANGERS level document-more in details and more accurate) Procurements/ Supplies Regulatory Trainings Technical/Trouble shooting batches/runs Process/Procedure qualification/validation (depending on the stage of transfer, Pivot batches,

    Bio-batches,.. can be included) Perform review Need to repeat any step Finalize transfer and Wrap-up Lessons-learned knowledge database

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 37

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 38

  • The suppliers list and detailed specifications of all required APIs, Excipients,Components, Packaging material, Reagents, QC Supplies . should be provided bythe Sending UnitThe criticality of using the exact same suppliers should be communicated with

    the Receiving UnitIt should be noted that sometimes all of the critical attributes might NOT be

    included in the CoA or Specification sheet or DossierIn case of inability of the Receiving Unit to procure the required item (with

    reasonable price and in a timely manner), the Sending Unit might facilitate itssupplyIn case the same suppliers are not used, the vendor selection procedure should

    be followed

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 39

  • !A Certain micronized purified API is exclusively supplied by the innovatorcompany, affecting dissolution, absorption and efficacy of the product

    A certain Ethanol grade is solely manufactured by one American Company,exclusively for one customer

    A certain PVC grade with low Water Vapor Transmission Rate (WVTR) is to beused by the Receiving Unit for packaging, while due to local production of PVC,imports of PVC is banned

    Imports of a certain specific HPLC column or UV spectrophotometer cell-holder/spacer, takes 5 months and double the real price, delaying the analyticaltransfer and making it very expensive

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 40

  • Pre-transfer Build transfer team and develop project charter (CEO/DIRECTORS level- estimates) Consolidate detailed knowledge for transfer and develop technology transfer protocol (MANGERS level

    document-more in details and more accurate) Procurements/Supplies

    Regulatory Trainings Technical/Trouble shooting batches/runs Process/Procedure qualification/validation (depending on the stage of transfer, Pivot batches, Bio-

    batches,.. can be included) Perform review Need to repeat any step Finalize transfer and Wrap-up Lessons-learned knowledge database

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 41

  • Authorizations (both for finished product and imported material, .) and Data-matrix codes(traceability), such as providing DIAFs (Drug Importing Application Form), CPPs (Certificate ofPharmaceutical Product), legalized documents, for the intermediate productsArtworks managementStability studies (what are accepted as commitment studies, which time points,)SUPAC and Dossier variationsSampling plansProduct registration at different stagesManufacturing and analysis change control and variationsBatch recordsLocal Dossier compilation (if relevant)Complaints, Retained samples, Pharmacovigilance, PQR .Other Documentations

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 42

  • Pre-transfer Build transfer team and develop project charter (CEO/DIRECTORS level- estimates) Consolidate detailed knowledge for transfer and develop technology transfer protocol (MANGERS level

    document-more in details and more accurate) Procurements/Supplies Regulatory

    Trainings Technical/Trouble shooting batches/runs Process/Procedure qualification/validation (depending on the stage of transfer, Pivot batches, Bio-

    batches,.. can be included) Perform review Need to repeat any step Finalize transfer and Wrap-up Lessons-learned knowledge database

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 43

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 44

  • Gap and risk analysis in trainings should be done in the Receiving Unit with a view fordetermining organizational shortfalls, and correcting them:Project management capabilityTeam-work ability, and culture and habitsGMP-compliant behavior, regulatory and safety issues, current state of product-related

    process understanding, manufacturing processes, documents, analytical methods,equipment, plant capabilitiesLanguage skillsNovel technologies (communications, IT, .)

    Trainings should be assessed and documentedHands-on experience/ Visit to Sending Unit should be arranged if necessary

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 45

  • Pre-transfer Build transfer team and develop project charter (CEO/DIRECTORS level- estimates) Consolidate detailed knowledge for transfer and develop technology transfer protocol

    (MANGERS level document-more in details and more accurate) Procurements/Supplies Regulatory Trainings Technical/Trouble shooting batches/runs Process/Procedure qualification/validation (depending on the stage of transfer, Pivot batches,

    Bio-batches,.. can be included) Perform review Need to repeat any step Finalize transfer and Wrap-up Lessons-learned knowledge database

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 46

  • Can be regarded as training and confidence-gaining opportunity for the transfer teamCan prevent waist of precious, and sometimes expensive materialSaves time and decreases the chances of failure in Validation/Qualification batches/ runsAllows modifying several affecting parameters in a wide range to gain a better view of the design space

    (particularly in case of scale-ups, batch-size changes, different machinery/technology in SU and RU)Allows some overlooked and unidentified issues/risks to surfaceAllows different processes in the process train to be assessed individually, with less time and continuity

    constraintAllows customization of batch records, documents . to be more adapted to the real processCan also be regarded as PQ of machinery

    Sometimes placebo materials are used, and sometimes the exact original material

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 47

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 48

  • Using placebo powders for tablet manufacturing, coating packaging

    Using placebo solutions in aseptic filling

    Using trial runs in dissolution and HPLC tests, before the official analyticaltransfer

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 49

  • Pre-transfer Build transfer team and develop project charter (CEO/DIRECTORS level- estimates) Consolidate detailed knowledge for transfer and develop technology transfer protocol

    (MANGERS level document-more in details and more accurate) Procurements/Supplies Regulatory Trainings Technical/Trouble shooting batches/runs Process/Procedure qualification/validation (depending on the stage

    of transfer, Exhibit, Bio-batches,.. can be included) Perform review Need to repeat any step Finalize transfer and Wrap-up Lessons-learned knowledge database

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 50

  • Lab-scale: 1001000 times less than production scale Formulation and packaging development, Early clinical and/or preclinical stages. CQAs

    Pilot batches-Scale-up batches: Process-development or optimization stage Preclinical and mid- to later-stage clinical

    evaluation Formal stability studies If supporting formal registration, size at

    least 10% of the production-scale batch or100,000 units, whichever is greater

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 51

    Exhibit batches-Qualification batches: In the manufacturing plant or the

    plant with similar equipment For process qualifications For stability studies The reason Exhibit batches are used

    by pharma/biopharma companies tosave time and money

    Hold time studies, change ofparameters within design space

  • Biobatch-Pivotal batch: The size of the biobatch adequate to represent the production batch size, and with production machinery i.e.

    no scale up beyond ten times. Scale up beyond ten times should be supported with a new biobatch/BW data to support the new size

    (possible exception for low-risk cases if well-defined). A biobatch should be the greater of 100,000 units, or not less than 1/10th the proposed production size. A biobatch of < 100,000 units may be accepted, but then no scale-up is allowed. This should be clearly

    indicated in reports for the product, as it affects allowable variations.

    Validation batchesThe actual size and parameters and machinery

    Commercial batches

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 52

  • At successful completion of all previous tasks, the Process/ProcedureValidation Batches/Runs, can take place.

    While it may be valuable to have personnel present from the SendingUnit, it is critical that the Receiving Unit actually execute the study(i.e., operate the equipment, take the samples, perform the testing,etc.) so that the study is truly representative of what will occur at thesite post-validation.

    The validation report should then be completed by the receiving site.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 53

  • Documentation of all observation (even those out of scope of ValidationProtocol);

    Constant precise observation even of the minute details Note-taking and Photographing, Video filming and any measure to help

    future review of events Trying to resolve any issue with minimum modification to the previously-

    approved protocol In case of need for change during the validation runs, it needs to be first

    discussed and approved by relevant authorities In setting of parameters within the agreed ranges or in case of need for

    change, try to modify one parameter at a time to be able to assess theeffects of individual parameters.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 54

  • Best practices:Plan extra runsPrepare for deviations & conduct in controlapprovals

    Follow in-process results closely19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 55

  • Know your process

    Understand your variability

    Build a Control Strategy early

    Establish a lifecycle

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 56

    Revisit your Risk Assessment

    Monitor the process andanalyze your results

    Continued processimprovement will lead you tothe Future!

  • Pre-transfer Build transfer team and develop project charter (CEO/DIRECTORS level- estimates) Consolidate detailed knowledge for transfer and develop technology transfer protocol

    (MANGERS level document-more in details and more accurate) Procurements/Supplies Regulatory Trainings Technical/Trouble shooting batches/runs Process/Procedure qualification/validation (depending on the stage of transfer, Pivot batches,

    Bio-batches,.. can be included) Perform review Need to repeat any step Finalize transfer and Wrap-up Lessons-learned knowledge database

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 57

  • The completed Validation Report should bereviewed against the previously setAcceptance Criteria and Objectives (bySending Unit and/or the Focal TechnologyTransfer Unit).In case of failure in these runs, an official

    Documented Root Cause Analysis should beconducted.The required steps should be modified

    (having in mind a Risk Assessment concept),in a documented and controlled manner, withthe involvement of all parties.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 58

    The technical runs can be repeated toassist in RCA The validation runs then should berepeated, until it can be concluded thatthe Process/ Product/Technology issuccessfully transferred:

    Assures consistency ofmanufacturingReproducibility of process designevaluated commerciallyProvides assurance of commercialreadiness

    At this stage the Project can be often wrapped up.

  • ! In most cases some minor non-critical issues will remain, which needCAPAs and follow ups for continuous improvement.

    The Sending Unit might still remain in contact with Receiving Unit to assist in: Continuous process verification (3-stage process validation approach) Control strategy Ongoing assurance process is in control Trending/Statistical Analysis/Proactive Improvement

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 59

  • Pre-transfer Build transfer team and develop project charter (CEO/DIRECTORS level- estimates) Consolidate detailed knowledge for transfer and develop technology transfer protocol

    (MANGERS level document-more in details and more accurate) Procurements/Supplies Regulatory Trainings Technical/Trouble shooting batches/runs Process/Procedure qualification/validation (depending on the stage of transfer, Pivot batches,

    Bio-batches,.. can be included) Perform review Need to repeat any step Finalize transfer and Wrap-up

    Lessons-learned knowledge database19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 60

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 61

    Review the deliverables vs. plan

    Review budget vs. plan

    Review timeline vs plan

    Revise templates/documents accordingly

  • Questionnaire to gather information

    Group meetings to finalize the output(Issue(s) faced within the project or the team)

    What did you chose to do about the issueand why?

    What was done well/not done well?

    Why do you think things went well/did notgo well?

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 62

    What should be done similarly next time?What could be improved next time?Are there any generalizable LLs to be gained

    from this experience? Are there any

    generalizable LLs to be gained from this

    experience?

    GapsList actionable LLsKey words:

    (for archiving purposes)

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 63

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 64

  • Differing technologies, machinery, control parameters

    Underestimating or overlooking analytical methods transfer

    No complete review of project charter by Top directors, leading to delays and lack oftimely support by them

    Lack or inefficiency of Quality Management Systems in any of the parties involved

    No proper development and validation of the case in the Sending Unit

    Overlooking trainings

    Differing batch sizes

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 65

  • Differing excipient/ packaging material suppliers

    Language/ communication gaps and non-responsive and non-open channels; No face-facevisits, Lack of transparency

    Lack of project management skills and human resources skills and technical skills in focalpersons

    Not considering plan Bs for changes outside of ones control area

    Lack of precise observation and documentation habits

    Unrealistic time-lines and commitments, leading to rush and subpar performance at the finalstages19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 66

  • Based on USP 39 (Since USP 35-2012) Transfer of Analytical procedures

    USP 39 Analytical Data-Interpretation and treatment WHO Technical Report Series, No. 961, 2011, Annex 7, WHO guidelines on transfer of

    technology in pharmaceutical manufacturing

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 67

    Sayeh MajzoobPharm. D., Ph. D. in Pharmaceutics; Pharma MBA

    Email address: [email protected]: +98 912 1366744

  • Analytical transfer:What is it, why should it be done? Definitions Is it required to officially perform Analytical Method Transfer: FDA warning lettersScope: In what situations might we need Analytical Method Transfer?Method Validation? Method Verification? Method Transfer?Types of Analytical Method Transfer: A risk-based approach-How it is done? :Comparative testingCo-validationRe-validation-Partial Revalidation/VerificationTransfer waiver

    Some possible designs of Analytical Method transferAcceptance criteria, Comparative testing, Statistical tests

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 68

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 69

    Steps in Analytical Method TransferPre-transfer:Build transfer team and develop project charter (CEO/DIRECTORS level- estimates)Consolidate detailed knowledge for transfer and develop technology transfer protocol (MANGERS level

    document-more in details and more accurate)RegulatoryTrainingsTechnical/Trouble shooting batches/runsProcess/Procedure qualification/validationPerform reviewNeed to repeat any step (non-conformance remedial action)Finalize transfer and Wrap-upLessons-learned knowledge database

    Case-study of an analytical transferPitfalls and possible reasons for failure in Analytical Method Transfer

  • USP 39 (Since USP 35-2012) Analytical transfer is the documented process that qualifies a

    laboratory (the receiving unit) to use an analytical test

    procedure that originated in another laboratory (the

    transferring unit), thus ensuring that the receiving unit has the

    procedural knowledge and ability to perform the transferred

    analytical procedure as intended*.

    *(Under actual conditions of use)19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 70

  • The firm failed to perform finished product test method transfers for 34products (W-187)

    The firm has failed to perform method validations, method verifications, ormethod transfers for any of the laboratory test methods used to test activepharmaceutical ingredients (W-187)

    Failure to establish and document the accuracy and reproducibility of testmethods employed. (W-186)

    For example, methods that were validated at one facility and transferred toxxx site are being used without a methods transfer or revalidation protocol.(W-186)

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 71

  • Sponsor company Contract labAnalytical development QC labsAcross different sites

    The same lab conditions Different lab conditions

    Existing instrumentation New instrumentation With different specifications With different technology

    Supplier of material ClientTransfer to new instruments with different instrument characteristics

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 72

  • For: APIs Excipients Finished Products Intermediates IPQC samples Packaging material Stability samples Cleaning validation analytical methods

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 73

  • Method Transfers are closely related to Validation/ VerificationMore challenging: multiple laboratories and companies involved; comparison

    and assessment of equivalence is the goal:Different approaches to Validation/ Verification and TransferDifferent expectations of what is an acceptable Validation/ TransferDifferent instruments and facilitiesThe method should be adequately validated at the Sending Unit prior

    to transferBalancing Act

    Adapt method to new facility/instrumentMeet new facility validation requirementsMaintain validated state of method

    Typically Analytical Method Transfers are mostly concerned with Accuracy and Precision(assuming the method should be validated at the sending unit).

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 74

  • Based on a risk assessment taking into account the complexity and criticality of theanalytical procedure and its purpose, as well as the experience and knowledge of the SUor RU.

    Comparative Testing (with appropriate justifications) - Analysis onsamples, from the same lot, by both laboratories and acceptance

    criteria is met.

    The acceptance criteria and variability are outlined in a transferprotocol.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 75

  • Co-validation of Laboratories- The transferring laboratory works with the receiving laboratory inan inter-laboratory validation effort at the transfer laboratory site. An assessment conducted,

    using a transfer protocol, to evaluate the reproducibility of the process.

    Receiving lab is part of original method validationTransferring and receiving lab conduct the same validation experimentsUseful for methods not (fully) validatedMust be based on pre-approved validation protocols and acceptance criteriaShould challenge all USP or ICH validation parametersInclude receiving lab in validation through inter-laboratory tests.Ensures harmonization of method at both sites

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 76

  • Revalidation/Partial Revalidation- Complete or partial method validationper Validation of Compendial Procedures by the receivinglaboratory:

    Mostly when the transferring labis not available or participating

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 77

  • Transfer waiver- Under certain circumstances, without comparison and generation ofinter-laboratory comparative data.Some scenarios that may justify the waiver:The new product's composition is comparable to that of an existing product

    and/or the concentration of active ingredient is similar to that of an existingproduct and is analyzed by procedures with which the receiving unit already hasexperience.The analytical procedure being transferred is described in the USP-NF, and is

    unchanged. Verification can apply in this case (see ).The analytical procedure transferred is the same as or very similar to a

    procedure already in use.The personnel/[equipment] in charge of the development, validation, or routine

    analysis of the product at the transferring unit are moved to the receiving unit.

    If eligible for transfer waiver, the receiving unit should document it.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 78

  • Some basic compendial procedures including, but not limited to: Loss on drying Residue on ignition Various wet chemical procedures such as acid value Simple instrumental determinations such as pH measurements

    However, for the application of already established routine procedures to compendialarticles tested for the first time, it is recommended that consideration be given to anynew or different sample handling or solution preparation requirements.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 79

  • Sample preparation and sample handling are the most critical issues and most commonreason for failure of method transfer.

    Based on the intended use of method the samples can be:Routine samples Expired Spiked samples Forced degradation samples Stability samples IPQC samples Intermediate products

    Trainings:Picture and video-based training- Face to face training and meetings (language barrier: can points be

    transferred in detail? Specialized translation)Tips (Formulation dependent,), expertise, experienceDetails of equipment, material, reagents, to be disclosed

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 80

  • As the dossier does not disclose the QC details, so some Closed part info. might berequested. The following data might be beneficial to be shared by the Sending UnitDevelopment data, SST results, unusual and OOS resultsHistory of critical analytical data (e.g., release and stability data) and rationale for proposed

    specificationsStability results and tests are an excellent source to evaluate the real routine performance of an

    analytical procedure

    If needed, change control and regulatory implications should be addressed.

    The analytical transfer should be made "Under actual conditions of use in the ReceivingLab.

    In some contexts, the main responsibility might be with RU, due to more experience withthe Product type or Test or Transfer.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 81

  • For older products it is recommended that analytical methods for stability arealso reviewed for adequacy at the time of transfer and agreed on.

    The choice of particular strategy needs justification.

    The type of transfer is defined for each method based on a risk assessmenttaking the complexity and criticality of the analytical procedure and its purposeinto account as well as the experience and knowledge of the RU.

    Possibility of a waiver

    Microbiological and Biological methods?19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 82

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 83

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 84

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 85

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 86

  • Setting acceptance limits/ criteria: Somewhat challenging and daunting task

    Types of comparisons: Direct comparison of mean values based on

    common industry practice (a priori) for each type oftest (Precision and Accuracy)

    !But with direct comparison, the number ofrepetition and variability are overlooked

    (Schuirmanns) Two one-sided t-test (TOST) (Notstudents t-test)

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 87

  • USP 39ANALYTICAL DATA-INTERPRETATION AND TREATMENT COMPARISON OF ANALYTICAL PROCEDURES

    APPENDIX F: EQUIVALENCE TESTING AND TOST Classical statistical hypothesis testing:e.g.: The null: Two means are equal.

    The alternative: Two means differ.The null hypothesis will rejected in favor of the alternative if the evidence is sufficient against the null.

    A common error is to interpret failure to reject the null as evidence thatthe null is true.

    Actually, failure to reject the null just means the evidence against the null was notsufficient.

    For example, the procedure used could have been too variable or the number ofdeterminations too small.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 88

  • "Null Until Proven Alternative" Look at it in terms of "innocent until proven guilty" in a courtroom:

    As the person analyzing data, you are the judge. The hypothesis testis the trial, and the null hypothesis is the defendant. The alternativehypothesis is like the prosecution, which needs to make itscase beyond a reasonable doubt (say, with 95% certainty).

    If the evidence presented doesn't prove the defendant is guiltybeyond a reasonable doubt, you still have not proved that thedefendant is innocent. But based on the evidence, you can't rejectthat possibility.

    So how would that verdict be announced? It enters the court recordas "Not guilty."

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 89

  • Therefore: To demonstrate similarity, (such as results from two laboratories), thenthe similarity should be set as the alternative hypothesis (not thedifference).

    A statistical test for an alternative hypothesis of similarity is referred to as anEQUIVALENCE TEST.

    It is important to understand that:"equivalence" does not mean "equality."

    Equivalence should be understood as "sufficiently similar" for the purposes ofthe laboratory(ies).

    As noted earlier in this chapter, how close is close enough, is something to be decideda priori.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 90

  • Accuracy and precision comparison:

    Comparison of the accuracy in two labs (USP

  • The lower and upper limits of the confidence interval onlyshow how large the true difference between the twoprocedures may be, not whether this difference is consid-ered tolerable.

    Such an assessment can be made only within theappropriate scientific context. This approach is oftenreferred to as TOST (two one-sided tests; USP39ANALYTICAL DATA-INTERPRETATION ANDTREATMENT: see Appendix F)

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 92

  • Possible reasons of False Significance or Non-significance if the difference inaverages is caused by applying simple T-tests:! A statistically significant difference may not be large enough tohave practical importance to the laboratory because: It may have arisen as a result of highly precise data or a larger sample size.

    ! On the other hand, it is possible that no statistically significantdifference is found, and yet an important practical difference cannotbe ruled out.This might occur, for example, if the data are highly variable or the sample size is too

    small.

    Thus, while the outcome of the t-test indicates whether or not a statisticallysignificant difference has been observed, it is not informative with regard to thepresence or absence of a difference of practical importance.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 93

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 94

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 95

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 96

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 97

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 98

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 99

  • Pre-transfer: Build transfer team and develop project charter (CEO/DIRECTORS level- estimates) Consolidate detailed knowledge for transfer and develop technology transfer protocol

    (MANGERS level document-more in details and more accurate) Regulatory Trainings Technical/Trouble shooting batches/runs Process/Procedure qualification/validation Perform review Need to repeat any step (non-conformance remedial action) Finalize transfer and Wrap-up Lessons-learned knowledge database

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 100

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 101

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 102

    Pre-transfer: MoU-Questionnaire-Audits-Visits-Detailed Contracts

    Build transfer team and develop project charter (CEO/DIRECTORS level- estimates)

    Consolidate detailed knowledge for transfer and develop technology transfer protocol (MANGERSlevel document-more in details and more accurate):

    Tips-Details-Previous method development data-Key analysts-Sample storage and handlings-MSDS-Safety points-Equipment comparison-Gap analysis-QRM-CAPAs

    Procurements/Supplies: Samples (Stability indicating: Expired-Forced degradation-Spiked)-Packaging material tests-

    Reference Standards-Columns-Cells, Spacers, Reagents-Solvents

  • RESPONSIBILITIESThe primary tasks of the Sending Unit are:Create the Transfer ProtocolExecute TrainingAssist in AnalysisAcceptance Criteria

    The Receiving Unit provides:Qualified InstrumentationPersonnelSystemsExecutes the Protocol

    The Sending Unit and the Receiving Unit are jointlyresponsible for issuing the final report.

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 103

  • Regulatory: Do the transfer strategy and QRM meet regulatory approval? Any variations compared to dossier-Is the receiving Lab accredited .

    Trainings: Transparent-Face to face-Tips-Pictures-Videos-Visit to the Sending lab

    Technical/Trouble shooting batches/runs: As not to waste resources, to be clearly oriented Trial runs and pose any questions/ambiguity to the Sending Laboratory

    Process/Procedure qualification/validationPerform reviewNeed to repeat any step (non-conformance remedial action)Finalize transfer and Wrap-upLessons-learned knowledge database

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 104

  • AnalyticalTransfer Protocolshould include:

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 105

  • Analytical transferreport form template tobe included forharmonization

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 106

  • Unrealistic risk assessment of the complexity and criticality of the method, and thetwo labs involvedChoosing un-scientific acceptance criteria and acceptance intervalDifferent equipment, in-experienced analysts and lab environmentMaterials/ Reagents/ Accessories from difficult-to-purchase suppliers (Columns,

    Special grade reagents,)Lack of Robustness and Reproducibility of method; Lack of full validationLack of documented and verified detailsNo open and responsive communication channel

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 107

  • Understand technology transfer and success criteria including:Forming the transfer team and developing the charterConsolidating knowledge for transfer and developing a technology

    transfer proposalIdentifying risks, conducting a risk assessments and developing

    technology transfer planExecuting the transferDeveloping the process (procedure) qualificationFinalizing the transfer and performing the reviewDeveloping an effective process for Technology Transfer including the

    exchange of knowledge between the sending unit and the receivingunit for drug substance, drug product and analytical procedures.Pitfalls

    19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 108

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 109

  • 19-Nov-16 Technology Transfer and Under-License Manufacturing in Pharmaceutical Industry- Sayeh Majzoob 110


Recommended